Biopact on Equifund CFP
PATENTED TECHNOLOGY THAT MAKES FIGHTING DISEASE SIMPLER, FASTER AND CHEAPER.
Raise to date: $45,585
Reporting Date: 03/29/2020
Key Stats
|
Minimum Raise
$20,000 |
Maximum Raise
$1,070,000 |
Likelihood of Max
|
|
Start Date
02/26/2020 |
Stop Date
06/30/2020 |
Days Remaining
91 |
|
Security Type
Common Stock |
Investment Minimum
$465 |
Deal Type |
Investment Summary
|
Status
Active |
# of Investors
36 |
% of Minimum Raised
228% |
% of Maximum Raised
4% |
|
Dollars Per Day to Reach Max
$11,257 |
DPD* Committed
$1,425 |
DPD* Category
$0 |
DPD* All Companies
$961 |
$45,585
Commitments
Weekly Commitments ($)
Aggregate Commitments ($)
SEC Filing Data from Kingscrowd
Biopact Cellular Transport, with a valuation of $30 million, is raising funds on Equifund Crowd Funding Platform. The company has a unique patented intracellular delivery technology that transports gene-editing technologies to cells effectively, safely, and affordably. The delivery mechanism of Biopact Cellular Transport will help reduce the cost and increase the effectiveness of therapies like CRISPR, TALEN, and CAR-T. Biopact Cellular Transport was founded by Kurt Swogger and is led by Randy Kinsel as the President. The current crowdfunding round of the company has a minimum target of $20,000 and a maximum target of $1,070,000. Biopact Cellular Transport’s MGMR technology is protected by 77 patents worldwide and has the potential to revolutionize cellular medicines.